Articles published by Bayer![]() ![]()
Bayer Initiates Phase III Study Program for Investigational Oral FXIa Inhibitor Asundexian
August 28, 2022
From Bayer
Via Business Wire
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() From Bayer
Via Business Wire
![]() From Bayer
Via Business Wire
![]() ![]() ![]() ![]() ![]() ![]() From Bayer
Via Business Wire
![]() ![]() ![]() ![]()
Bayer Highlights Advancements of Agriculture Industry’s Most Prolific R&D Pipeline
February 16, 2022
From Bayer
Via Business Wire
![]()
Bayer Receives FDA Fast Track Designation for asundexian Stroke Program
February 10, 2022
From Bayer
Via Business Wire
![]() From Bayer
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|